TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

NCT05441956 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: TGRX-326

Sponsor

Shenzhen TargetRx Co., Ltd.

Collaborators

[object Object]